NEURESCUE Device as an Adjunct to In-Hospital Cardiac Arrest (ARISE)

ClinicalTrials.gov ID: NCT05444049

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05444049. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Feasibility Study of the NEURESCUE Device as an Adjunct to In-Hospital Cardiac Arrest

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body. The objective of this study is to investigate the feasibility of the NEURESCUE device as an adjunct to Advanced Cardiac Life Support (ACLS) in adults with cardiac arrest.

Study identification

NCT ID: NCT05444049
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: neurescue; Industry
Enrollment: 6 participants

Conditions and interventions

Conditions

Interventions

NEURESCUE device Device

Device

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 8, 2022 (Actual)
Primary completion: Sep 30, 2024 (Actual)
Completion: Sep 30, 2024 (Actual)
Last update posted: Oct 9, 2025

2022 – 2024

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Long Beach Medical Center	Long Beach	California	90806	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05444049, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 9, 2025 · Synced Nov 15, 2026